Anti-factor IXa Aptamer reduces propagation of thrombin generation in plasma anticoagulated with warfarin

Thrombosis Research

Volumn 125, Issue 5, 2010, Pages 432-437

  Szlam, Fania ^a   Luan, Deyan ^b   Bolliger, Daniel ^c   Szlam, Arthur D ^d   Levy, Jerrold H ^a   Varner, Jeffrey D ^b   Tanaka, Kenichi A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cornell University   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti Factor IXa Aptamer; Thrombin Generation; Warfarin

Indexed keywords

ACTIN; BLOOD CLOTTING FACTOR 9A INHIBITOR; BLOOD CLOTTING INHIBITOR; RB 006; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING FACTOR 7 DEFICIENCY; COMPUTER SIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; IN VITRO STUDY; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTHROMBIN TIME; THROMBIN TIME;

ANTICOAGULANTS; APTAMERS, NUCLEOTIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FACTOR IXA; HUMANS; PLASMA; THROMBIN; WARFARIN;

EID: 77951667136     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.11.018     Document Type: Article

References (32)

1. Tanaka K.A., Szlam F., Rusconi C.P., and Levy J.H. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. Thromb Haemost 101 (2009) 827-833
2. Butenas S., and Mann K.G. Blood coagulation. Biochemistry (Mosc) 67 (2002) 3-12
3. van 't Veer C., Golden N.J., Kalafatis M., and Mann K.G. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. J Biol Chem 272 (1997) 7983-7994
4. Luan D., Zai M., and Varner J.D. Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies. PLoS Comput Biol 3 (2007) 1347-1358
5. D'Angelo A., Vigano-D'Angelo S., Esmon C.T., and Comp P.C. Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation. J Clin Invest 81 (1988) 1445-1454
6. Basic K.B., and Pharmacology C. 8th edition (2001), Mcgraw-Hill, New York
7. Hemker H.C., Giesen P., Al Dieri R., Regnault V., de Smedt E., Wagenvoord R., et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33 (2003) 4-15
8. Tanaka K.A., Szlam F., and Levy J.H. The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation. Br J Haematol 134 (2006) 77-82
9. Espana F., Estelles A., Griffin J.H., Aznar J., and Gilabert J. Aprotinin (trasylol) is a competitive inhibitor of activated protein C. Thromb Res 56 (1989) 751-756
10. Butenas S., Orfeo T., Kalafatis M., and Mann K.G. Peptidomimetic inhibitors for activated protein C: implications for hemophilia management. J Thromb Haemost 4 (2006) 2411-2416
11. De Nanteuil G., Gloanec P., Beguin S., Giesen P.L., Hemker H.C., Mennecier P., et al. Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders. J Med Chem 49 (2006) 5047-5050
12. Wielders S.J., Beguin S., Hemker H.C., and Lindhout T. Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available. Arterioscler Thromb Vasc Biol 24 (2004) 1138-1142
13. Kravtsov D.V., Matafonov A., Tucker E.I., M.-f. S., Walsh P.N., Gruber A., et al. Factor XI contributes to thrombin generation in the absence of factor XII. Blood 114 (2009) 452-458
14. Cushman M., O'Meara E.S., Folsom A.R., and Heckbert S.R. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood 114 (2009) 2878-2883
15. Aird W.C. Vascular bed-specific thrombosis. J Thromb Haemost 5 Suppl 1 (2007) 283-291
16. Esmon C.T. The protein C pathway. Chest 124 (2003) 26S-32S
17. Kearon C., Johnston M., Moffat K., McGinnis J., and Ginsberg J.S. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med 158 (1998) 1140-1143
18. Sheth S.B., DiCicco R.A., Hursting M.J., Montague T., and Jorkasky D.K. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 85 (2001) 435-440
19. Ansell J., Hirsh J., Hylek E., Jacobson A., Crowther M., and Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008) 160S-198S
20. Briede J.J., Tans G., Willems G.M., Hemker H.C., and Lindhout T. Regulation of platelet factor Va-dependent thrombin generation by activated protein C at the surface of collagen-adherent platelets. J Biol Chem 276 (2001) 7164-7168
21. Oliver J.A., Monroe D.M., Church F.C., Roberts H.R., and Hoffman M. Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. Blood 100 (2002) 539-546
22. Sixma J.J., and van den Berg A. The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A. Br J Haematol 58 (1984) 741-753
23. Comp P.C. Coumarin-induced skin necrosis. Incidence, mechanisms, management and avoidance. Drug Saf 8 (1993) 128-135
24. Warkentin T.E., Elavathil L.J., Hayward C.P., Johnston M.A., Russett J.I., and Kelton J.G. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 127 (1997) 804-812
25. Srinivasan A.F., Rice L., Bartholomew J.R., Rangaswamy C., La Perna L., Thompson J.E., et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 164 (2004) 66-70
26. Gruber A., and Hanson S.R. Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood 102 (2003) 953-955
27. Kleinschnitz C., Stoll G., Bendszus M., Schuh K., Pauer H.U., Burfeind P., et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 203 (2006) 513-518
28. Salomon O., Steinberg D.M., Koren-Morag N., Tanne D., and Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 111 (2008) 4113-4117
29. Warkentin T.E., and Sheppard J.A. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 20 (2006) 259-272
30. Olson S.T., Swanson R., Raub-Segall E., Bedsted T., Sadri M., Petitou M., et al. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin. Thromb Haemost 92 (2004) 929-939
31. Greinacher A., Alban S., Omer-Adam M.A., Weitschies W., and Warkentin T.E. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res. 122 (2008) 211-220
32. Rusconi C.P., Roberts J.D., Pitoc G.A., Nimjee S.M., White R.R., Quick Jr. G., et al. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 22 (2004) 1423-1428